PT - JOURNAL ARTICLE AU - Laurence Chu AU - David Montefiori AU - Wenmei Huang AU - Biliana Nestorova AU - Ying Chang AU - Andrea Carfi AU - Darin K. Edwards AU - Judy Oestreicher AU - Holly Legault AU - Bethany Girard AU - Rolando Pajon AU - Jacqueline M. Miller AU - Rituparna Das AU - Brett Leav AU - Roderick McPhee TI - Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) AID - 10.1101/2021.09.29.21264089 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.29.21264089 4099 - http://medrxiv.org/content/early/2021/10/01/2021.09.29.21264089.short 4100 - http://medrxiv.org/content/early/2021/10/01/2021.09.29.21264089.full AB - Rising breakthrough infections of coronavirus-2 (SARS-CoV-2) in previously immunized individuals has raised concerns for a booster to combat suspected waning immunity and new variants. Participants immunized 6-8 months earlier with a primary series of two doses of 50 or 100 µg of mRNA-1273 were administered a booster injection of 50 µg of mRNA-1273. Neutralizing antibody levels against wild-type virus and the Delta variant at one month after the booster were 1.7-fold and 2.1-fold higher, respectively, than those 28 days post primary series second injection indicating an immune memory response. The reactogenicity after the booster dose was similar to that after the second dose in the primary series of two doses of mRNA-1273 (50 or 100 µg) with no serious adverse events reported in the one-month follow-up period. These results demonstrate that a booster injection of mRNA-1273 in previously immunized individuals stimulated an immune response greater than the primary vaccination series.Competing Interest StatementWenmei Huang, Ying Chang, Judy Oestreicher, Holly Legault, Biliana Nestorova, Bethany Girard, Rolando Pajon, Jacqueline M.Miller, Andrea Carfi, Darin K. Edwards, Rituparna Das, Brett Leav, and Roderick McPhee are employees of Moderna, Inc., and may hold stock/stock options in the company.Clinical TrialNCT04405076Funding StatementParts A and B of the phase 2 trial (mRNA-1273 P201 trial/open-label extension; NCT04405076) were supported in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00034, and Moderna, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB was Advarra, Inc., Columbia, MD.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available in this article and in its Supplementary Information.